Salarius Pharmaceuticals, Inc. clarifies misinformation on S&P CapIQ regarding their merger with Decoy Therapeutics and confirms their stock continues to trade on the Nasdaq under “SLRX.” The company recently completed an $8 million public offering and merger with Decoy, resulting in a combined cash of $14 million and 5.9 million shares outstanding. Decoy aims to advance a pan-coronavirus antiviral, a broad-acting antiviral for flu, COVID-19, and RSV, and a peptide drug conjugate for GI cancers in the next 12 months. Salarius focuses on developing peptide conjugate therapeutics through their IMP3ACT platform using AI and ML.

Read more at GlobeNewswire: Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform